Regulatory approval of anti-cancer drugs occurs typically after demonstration of clinical benefit in registration trials. Over the last 15 years, new drug development has focused on numerous mechanisms of action including conventional cytotoxic agents, inhibition of oncogenic signaling pathways, angiogenesis and immune modulation. In recent years, there has been substantial enthusiasm for immunotherapy agents [1–4]. However, the differential efficacy, safety, tolerability and price of these agents relative to other anti-neoplastic drugs are uncertain.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oW8f1A
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Bromodomain proteins function as epigenetic readers that recognize acetylated histone tails to facilitate the transcription of t...
-
Objectives To optimise medical students’ early clerkship is a complex task since it is conducted in a context primarily organised to take ca...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
C. Julian Chen'Correspondence information about the author C. Julian ChenEmail the author C. Julian Chen, Donald A. Miller DOI: https://...
-
ACS Nano DOI: 10.1021/acsnano.7b00032 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lNPpuk via...
-
Abstract Polychlorinated biphenyls (PCBs), a group of 209 congeners that differ in the number and position of chlorines on the biphenyl rin...
-
1 abqls-210rm.html Read the latest Journal of Clinical Neurophysiology - Vol. 37, No. 1, January 2020.eml 2 agx3v-nxz96.html Read the late...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου